Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02156492
Recruitment Status : Completed
First Posted : June 5, 2014
Results First Posted : October 10, 2018
Last Update Posted : October 10, 2018
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The main purpose of this study is to investigate how the body responds to evacetrapib and to evaluate the safety and the effect of evacetrapib, alone and in combination with selected statins, in healthy Chinese participants. The study has 2 parts. Part one will last up to 4 weeks and part two will last up to 5 weeks, not including screening. Participants may only enroll in one part.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Evacetrapib Drug: Simvastatin Drug: Atorvastatin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Study of Evacetrapib With Selected Statins in Healthy Chinese Subjects
Study Start Date : June 2014
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Evacetrapib Single
Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
Drug: Evacetrapib
Administered orally.
Other Name: LY2484595

Experimental: Evacetrapib Multiple
Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.
Drug: Evacetrapib
Administered orally.
Other Name: LY2484595

Active Comparator: Simvastatin
Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.
Drug: Simvastatin
Administered orally.

Experimental: Evacetrapib and Simvastatin
Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.
Drug: Evacetrapib
Administered orally.
Other Name: LY2484595

Drug: Simvastatin
Administered orally.

Active Comparator: Atorvastatin
Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.
Drug: Atorvastatin
Administered orally.

Experimental: Evacetrapib and Atorvastatin
Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.
Drug: Evacetrapib
Administered orally.
Other Name: LY2484595

Drug: Atorvastatin
Administered orally.




Primary Outcome Measures :
  1. Pharmacokinetics (PK): Area Under Curve (AUC 0-inf) of Evacetrapib [ Time Frame: Part 1: Day 1 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours Postdose ]
    Pharmacokinetic (PK) parameter estimates from evacetrapib concentrations following single dose and daily dose of 130 mg evacetrapib.

  2. PK: Maximum Concentration (Cmax) of Evacetrapib [ Time Frame: Part 1: Day 1 and Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14: Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours Postdose ]
    Pharmacokinetic parameter estimates from evacetrapib following single dose and daily doses of 130 mg.

  3. PK: Time to Maximum Concentration (Tmax) of Evacetrapib [ Time Frame: Part 1: Day 1 Predose on Day 1 or Day 14 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours postdose. Part 2: Predose on Day 14 at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose. ]
    Pharmacokinetic parameter estimates of evacetrapib following single and daily doses of 130 mg evacetrapib.

  4. PK: AUC of Evacetrapib Alone and With Simvastatin or Atorvastatin [ Time Frame: Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose ]
    Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily AUC (0-24).

  5. PK: Cmax of Evacetrapib Alone and With Simvastatin or Atorvastatin [ Time Frame: Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose. ]
    Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily.

  6. PK: Tmax of Evacetrapib Alone and With Simvastatin or Atorvastatin [ Time Frame: Part 2: Predose on Day 14 and 22 and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose. ]
    Pharmacokinetic parameter estimates of Tmax of evacetrapib following 130 mg daily dose alone or with 40 mg Simvastatin or 20 mg Atorvastatin. Tmax of simvastatin and atorvastatin.


Secondary Outcome Measures :
  1. Effect of Evacetrapib Single and Multiple Doses on High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG) [ Time Frame: Single Dose Day 2 and Multiple Dose Day 22 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Are native Chinese and living in China.
  • Are overtly healthy males or females as determined by medical history and physical examination.
  • Female participants:

    • Women not of child-bearing potential
    • Women of child-bearing potential must correctly use 2 forms of reliable contraception to avoid getting pregnant during the study and for 3 months after the study is completed.
  • Body Mass Index: 19.0 to 24.0 kilogram per square meter (kg/m^2)
  • BP and pulse rate at both supine and standing positions of approximately a systolic BP ≤ 140 millimeter of mercury (mm Hg), and diastolic BP ≤ 90 mm Hg
  • Participants with untreated hypercholesterolemia may be included if not on an herbal or other traditional Chinese medicines (TCM)
  • Have no known liver disease
  • Have given written informed consent

Exclusion Criteria:

  • Are currently enrolled in a clinical trial involving an investigational product (IP) or off-label use of a drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have known allergies to evacetrapib, simvastatin, or atorvastatin, related compounds or any components of the formulation
  • Have previously completed or withdrawn from this study or any other study investigating evacetrapib, and have previously received the IP within 3 months.
  • Have a history within the last year or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
  • Show evidence of significant active neuropsychiatric disease.
  • Regularly use known drugs of abuse
  • Are women with a positive pregnancy test or women who are lactating.
  • Have used or intend to use over-the-counter or prescription medications (including vitamins/mineral supplements) or TCM 14 days prior to the first dose and during the study.

    • Hormonal contraceptives are permitted.
  • Use of any drugs or substances that are known to be substrates, inducers, or inhibitors of organic anion transporting polypeptide 1B1 (OATP1B1), or of any other transporters involved in simvastatin or atorvastatin disposition, or of any drugs or substances that are known to be strong inducers or inhibitors of cytochrome P450 3A (CYP3A) within 30 days prior to the first dose and throughout the study.
  • Donated blood of >400 mL within the last month.
  • Drink alcoholic beverages with intake that exceeds 28 units per week (males) and 21 units per week (females), or are unwilling to stop alcohol consumption 48 hours prior to dosing until discharge from the clinical research unit (CRU) (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
  • Are unwilling to comply with the dietary requirements/restrictions during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02156492


Locations
Layout table for location information
China
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Beijing, China, 100034
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT02156492    
Other Study ID Numbers: 14467
I1V-MC-EIAM ( Other Identifier: Eli Lilly and Company )
First Posted: June 5, 2014    Key Record Dates
Results First Posted: October 10, 2018
Last Update Posted: October 10, 2018
Last Verified: February 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Atorvastatin
Simvastatin
Evacetrapib
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors